Searched for
ACCORD BIOPHARMA
Donald Trump Avenue: India now has a road named after US president. Here is where and whyHyderabad has renamed a road near the US Consulate to "Donald Trump Avenue" to mark America's 250th Independence Day. The move by the Telan...- L’Oréal adds Innovist to cart; HealthQuad's new fundHappy Friday! Personal care giant L’Oreal has acquired a majority stake in Innovist in India’s biggest D2C deal. This and more in today’s E...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- GSK in talks to buy cancer biotech Nuvalent for more than $9 billionBritish drug giant GSK is reportedly in talks to acquire cancer drugmaker Nuvalent. The deal could be worth over nine billion dollars. Disc...
- Japanese biotech developing tooth-regrowing drug raises $5.3 million to advance human trialsToregem BioPharma has secured $5.3 million to advance its experimental tooth-regeneration drug, TRG035, into Phase II clinical trials. The ...
- J&K attracts record ₹5,824 crore investment in 2025-26, 13x jumpJammu and Kashmir has achieved a record investment of over ₹5,800 crore in 2025-26. This marks a significant jump, thirteen times higher th...
- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Moderna stocks: MRNA shares jump in US Stock market today after pharma giant surpasses Wall Street estimatesModerna had earlier posted a loss of $2.52 per share a year earlier, while analysts expected a loss of $3.96 per share.
- FM Nirmala Sitharaman to push biopharma, semiconductor missions in NorwayFinance Minister Nirmala Sitharaman is in Oslo to boost India's bio-pharma and semiconductor sectors. She will meet Norwegian Prime Ministe...
- Intas Pharma completes acquisition of UDENYCA biosimilar for $558 millionIntas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. ...
- India emerging as favourable destination to conduct global clinical trials: ReportThe joint report by the USA India Chamber of Commerce & PwC India titled, “Clinical Trial opportunities in India” which will be released at...
- Top government officials, leaders from industry, academicians to take part in India-US Biopharma and Healthcare SummitNITI Aayog CEO Amitabh Kant, Pfizer CEO Dr Alberta Bourla, National Institutes of Health (NIH) Director Dr Francis Collins and Food and Dru...
- India's health and biopharma sector deserve more attentionIndia's health and innovative and biopharma sector deserves better attention from the government to help realise its full potential
- Biotech sector likely to touch $7 billion by FY15: StudyThe country's biotechnology sector is divided into five segments based on the products and services offered - bio pharmaceuticals, bio serv...
- Biocon No 6 among top 20 global Biotech employersBiotechnology major Biocon today said it has been ranked No 6 on the annual global 'Top Twenty Employers' list for the Bio-Pharma sector by...
- Policy, infrastructure main hurdles in Indian pharma R&D: ReportThe McKinsey report commissioned by the US-India Chamber of Commerce would be released at the US-India BioPharma and Healthcare Summit 2013...
- 'India has potential to be global hub of bio-pharma sector'Noting that India has the ability to be a "global hub" in the bio-pharma and healthcare sector, industry leaders have said that steps need ...
- India can become innovation hub for bio-pharma: BCG reportEmerging markets will drive 70% of growth in the pharma industry and India will require supportive policies to leverage the BioPharma.
- 'Indian bio-pharma R&D spending could grow to $25 bn by 2025'India's bio-pharma sector may see a surge in R&D spending to about $25 billion in the next 15 years, according to a Boston Consulting Group...
- Revenues of Indian biotech sector surge to $4 bn in 2010-11The biotech industry, without the life sciences education component, recorded revenue growth of 21.5 per cent vis-a-vis 2009-10 revenues of...
Load More
